ZimVie Inc.

Good day, and thank you for standing by. Welcome to the ZMV second quarter 2022 earnings call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during this session, you'll need to press star 1-1 on your telephone. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Marissa Beisch, Investor Relations. Please go ahead.

Hi, and thank you all for joining today's call. Earlier today, Zimdy released financial results for the quarter ended June 30, 2022. A copy of the press release is available on the company's website, Zimdy.com, as well as SEC.gov. Before we begin, I'd like to remind you that management will make comments during this call that include forward-looking statements. Actual results may differ materially from those indicated by the forward-looking statements due to a variety of risks and uncertainties. Please refer to the company's 2021 Form 10-K and subsequent SEC filings for a detailed discussion of these risks and uncertainties. Additionally, the discussion on this call will include certain non-GAAP financial measures. Reconciliations of these measures to the most directly comparable GAAP financial measures are included within the earnings release and or the investor deck issued today found on the investor relations section of the company's website, Zimdy.com. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, August 10, 2022. ZMV disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. And with that, I will turn the call over to Vafa Jamali, President and Chief Executive Officer of ZMV.

Good afternoon, and thank you all for joining us. I'm on the call today with Rich Heppenstall, our Chief Financial Officer. I'd like to kick off our call by reacquainting investors with who we are at Zimbi, including our dental and spine businesses, and then reviewing our financial performance for the quarter ended June 30th, 2022, our first full quarter as a newly independent company. Zimbi is a global medical technology leader dedicated to restoring life for dental and spine patients. and we participate in a $20 billion global market opportunity across those markets. We are the number five largest player in the worldwide dental market and the number six in spine. We have over 20 brands trusted by clinicians and surgeons worldwide. We operate in 70-plus countries, and we have approximately 2,700 team members. Our vision is that everyone deserves to feel better, healthier, and stronger. Our mission is to advance clinical technology foundational to restoring daily life. As I mentioned earlier, we have the fortune of being a leading player in two substantial and growing markets. Our product platforms address a broad set of critical patient needs across those markets and are substantially differentiated from competitive solutions in several cases. Our dental business is very well positioned in the growing global dental, implant, and biomaterials market. Within this segment, we continue to operate in three key categories, dental implant solutions, which is our largest contributor, biomaterials which support the implant, including its durability and sustainability, and digital dentistry. Digital dentistry is an emerging technology that provides significant workflow support to the clinician across their office and, derivatively, both improves the quality of the implant while reducing the time that a patient spends in the chair. As we scale our digital dentistry solutions, we are also driving strong adoption and pull-through of our implant business. In the second quarter, I'm especially pleased to highlight our launch of the T3 Pro tapered implant and the ENCODE Emergence healing abutment, designed to optimize restorative care and aesthetics. Both the T3 Pro and ENCODE Emergence reflect significant innovation to ZymV's previous products and promise an optimized implant experience for both dentists and patients. Both products have recognized strong early traction, with T3 Pro receiving positive feedback on primary stability and favorable reception to encode emergence centered on seeding at the tissue level, enhanced ease of use, and eliminating the need for bone profiling. Based on recent market data, we see T3 Pro capturing modest early share in the premium implant segment. Our spine business comprises a broad portfolio of spine implants, instruments, and biologics, as well as bone healing solutions. In addition to our largest spine segment of core and complex solutions, we also have exposure to two exciting emerging categories, motion preservation devices and minimally invasive surgery. Motion preservation is an area we are actively leading and remain very excited about, including MobiSea, the market-leading cervical disc replacement, and the Tether, a novel treatment for pediatric scoliosis. Minimally invasive surgery, which typically benefits from the addition of enabling technology, is an area in which we intend to further expand. Regarding our motion preservation solutions, I'm excited to highlight our recent receipt of a positive policy decision from Anthem for the tether device, which expands potential treatment eligibility to patients indicated for anterior vertebral body tethering, or AVBT, within the 30 million plus members covered under Anthem Blue Cross Blue Shield. We have seen firsthand the positive impact that the tether has had on the lives of children and their families, and we're optimistic that this decision will pave the way for additional favorable policy changes to continue expanding therapy access. Turning to our performance as we exit the first full quarter as an independent company, I would like to reiterate that it remains very early days at Zimbi. Nonetheless, I'm pleased to announce we recognize $233.4 million in total net sales for the second quarter, declining roughly 8% year-over-year on a constant currency basis, but offering the baseline against we are confident we can grow over time. Our results in the quarter were impacted to some extent by shortage of facility staffing and the elective nature of some of our procedures, dynamics which many of our peers have also stated. However, we are not allowing a challenging macro environment to detract from our focus on strengthening our foundation and positioning to drive future growth. For example, by launching two new products in dental, which I referred to earlier, the T3 Pro and the Encode Emergence and Healing Abundant, we intend to stay at the forefront of the premium implant digital dentistry markets by delivering a cadence of dental product enhancements over the coming year and beyond. As I touched on earlier, we saw the culmination of years of our team's work driving awareness of the tether's value in pediatric scoliosis in the form of a positive policy decision from Anthem. Although the Tether contributes a smaller piece of our spine portfolio today, insurance coverage has proven the greatest headwind to adoption in the past, and we expect the Tether to grow meaningfully as access improves over time. I would also like to highlight that we improved our cash balance by approximately $25 million sequentially from first quarter end through second quarter end, closing June with $130 million in cash and equivalents. We drove cash flow improvement through greater fiscal discipline, including spending scrutiny and monetization of certain aspects of our balance sheet, as Rich will detail shortly. As we said during our analyst investor day earlier this year, we are committed to advancing our operational efficiency of our business, including improving cash flow and reducing leverage over time. We are pleased with our early progress to increase cash, providing greater forward flexibility and confidence in achieving those goals. I will now hand the line over to Rich Heppenstall, our Chief Financial Officer, to review more details of our second quarter performance and financial outlook.

Thanks, Staffa, and good afternoon, everyone. I'll begin by reviewing our second quarter 2022 results, and we'll then close by providing commentary on our outlook for the full year 2022. Beginning with sales. Total third-party net sales for the second quarter of 2022 were $233.4 million, a decrease of 11.5% on a reported basis and 8.3% in constant currency when compared to the prior year period. Shifting to our two segments, Global Dental's third-party net sales were $118.2 million, representing a 1.8% decrease on a reported basis and a 2.9% increase in constant currency when compared to the prior year period, primarily driven by implant and digital dentistry net sales growth and an extra selling day in Q2 of 2022, offset by foreign currency exchange headwinds, mainly net sales denominated in the euro. Geographically, dental's U.S. third-party net sales of $70.2 million increased by 3.7%. Outside of the U.S., sales of $48.0 million decreased by 8.9% on a reported basis, but increased 1.9% when excluding the impact of currency. Strong double-digit implant growth in the U.S. was fueled by pull-through from our digital dentistry and biomaterials offerings and leveraging our medical education programs. but was partially overshadowed by a more challenging macroeconomic environment outside of the U.S., particularly in Europe. Global Spines third-party net sales were $115.2 million in the second quarter of 2022, a 19.6% decrease on a reported basis, and a 17.8% decrease in constant currency when compared to the prior year period. The decrease in spine sales is driven by the exit of certain unprofitable markets in late 2021, the discontinuation of products as part of our brand rationalization program, the impact of the net sales retained by Zimmer Biomet until we complete our separation activities in certain markets, and continued competitive pressures in the spine market. When adjusting for these items and taking into consideration one additional selling day, fine sales decreased by 13.2% and 11.3% on a reported and constant currency basis, respectively. Adjusted growth profit was $153.4 million compared to $177.9 million in the prior year period. Adjusted growth margin was 65.7%, a decrease of 180 basis points when compared to 67.5% in Q2 of 2021. The decline versus prior year is primarily due to lower net sales, which drives higher excess and obsolete inventory in spine, partially offset by higher gross margins in our dental segment due to a higher margin contribution from implant growth. Adjusted research and development expenses in the percentage of third-party sales of 5.5% is flat to the prior year period. Adjusted selling, general, and administrative expenses of $124.5 million, or 53.3% of third-party net sales, reflects a reduction of $13.0 million over the prior year period. The decline year-over-year is due to less variable selling expenses from lower net sales, time delays of cost to continue to stand up Zimbi as an independent public company, and operational initiatives intended to reduce our cost structure. G&A, as a percentage of third-party sales, increased 120 basis points year-over-year. Adjusted EBITDA of $31.3 million or 13.4% of third-party sales reflects a decrease of 110 basis points from 14.5% in the prior year period. In constant currency, adjusted EBITDA was $32.6 million, or 13.5% of sales. Our profit margins are generally naturally hedged against currency fluctuations, which means that the volatility we're seeing in the global currency markets. In addition, we instituted a balance sheet hedging program immediately following the spin to hedge against currency transaction risk. This program is working as designed, reflected by a modest $0.5 million of currency gains making their way into our income statement in Q2 of 2022. Adjusted earnings per share was 67 cents on a fully diluted weighted average share count of 26.1 million shares. During the quarter, we realized a tax benefit of $6.3 million on an adjusted basis, or approximately $0.24 per share, due in large part to account for income tax previously recognized for intercompany inventory when we were part of Zimmer BuyMet. This inventory is non-taxable to ZMV as it is sold. Touching on working capital and liquidity, We are in the early stages of capitalizing on the strength of assets on our balance sheet with a focus on optimizing the allocation of capital and the monetization of certain assets to drive cash and thus increase financial flexibility. Our early efforts have resulted in a reduction in net inventory of $20.3 million since December of 2021 and a reduction of $8.6 million in the planned amount of capital spent on spine instruments. We ended the second quarter with approximately $130 million of cash and equivalents, up $26 million from $104 million at March 2022. This includes approximately $22 million of cash earmarked to settle certain post-spin related transactions and to fund ERP implementations to decouple from our prior parent company. I'll now turn to our revised full year 2022 outlook. Inclusive of a greater than anticipated impact of foreign exchange headwinds, we are revising our full year 2022 net sales outlook to a range of $915 million to $930 million. This compares to our prior guidance of $1.0 billion in net sales. Over $30 million, or slightly less than half of our total reduction, is due to foreign exchange headwinds of prevailing rates. As it relates to the segments, we now expect full year 2022 net sales growth in the mid-single digits on a constant currency basis for our dental business. This is at the lower end of our prior expectations for mid to high single digit growth due to macroeconomic headwinds, particularly in Europe. For our spine segment, we now expect full year 2022 net sales to decline in the low double digits versus our prior expectation for mid to high single digits. The decline is due to choppiness in procedural volumes, China volume-based procurement acceleration into 2022, and commercial execution challenges. We have made progress identifying inconsistencies in our team's commercial approach and continue to execute against our longer-term initiatives to return this business to growth. We are pleased with the operational actions we've taken in our first few months since spin to right-size the business and optimize our cost structure. Thus, we are maintaining our adjusted EBITDA margin range of 13.1% to 13.6%. Turning to our bottom line expectations, we are revising our full year 2022 adjusted earnings per share outlook to a range of $1.80 to $2 per share from $2.10 to $2.30 per share previously. This is due in large part to the impact of lower revenue and higher interest expense, partially offset by the full-year impact of the tax benefit we realized in Q2. Before I close and hand back over to Vapa, I want to underscore that we've launched a number of operational initiatives in the four months since SPIN to control operating expenses, right-size our business, rationalize our real estate and geographic footprint, and monetize the strength of assets on our balance sheet. Although the realization of many of these projects will manifest themselves in the income statement over coming quarters, we are seeing an immediate benefit to liquidity and financial flexibility as I just discussed. We are pleased with our progress in the short time since spent and will continue to apply our disciplined financial framework as we continue to operationalize the business. With that, I'll now turn the call back over to the back up.

Thank you, Rich. I want to close our call by looping back to the positive policy decision from Anthem Blue Cross Blue Shield for the tether, expanding potential treatment eligibility within their 30-plus million members covered under Anthem Blue Cross Blue Shield. Our tether device is a first-of-its-kind non-fusion scoliosis treatment and the first and only FDA-approved device for anterior vertebral body tethering. Its humanitarian device exemption, HDE, was granted based on over seven years of clinical data validating its safety and effectiveness in scoliosis correction. Over 1,200 children have received the tether since HDE approval in August 2019, with approximately 50 U.S. surgeons performing the procedure. Today, I want to highlight the story of a 13-year-old male patient with scoliosis, for whom coverage was the prior barrier to therapy, All the doctors at Children's Hospital Colorado recommended VBT. His original claim and appeal were denied. As the scoliosis worsened, his family spent hours on the phone to fight this. Just three weeks ago, the family got word that insurance would cover the procedure due to the updated policy deeming the treatment medically necessary for indicated patients. They were thrilled to access the best option for their son. Expanded coverage removes a significant barrier to treatment for many patients like this one, and we are optimistic that Anthem's decision will pave the way for even greater therapy from additional insurers over time. In summary, we are pleased to be doing what we set to do from the time of our spanges a few months ago, which is operate the company with greater efficiency and leverage our differentiated therapies like the Tether to lay the foundation for future growth. This remains our priority as we continue our mission to transform patients' lives. With that, I want to thank you for your time and open it up for any questions.

Thank you. Our first question comes from Robbie Marcus. One moment.

Hi, can you hear me okay?

Yes, go ahead. Yeah, Robbie, go ahead.

Oh, great. Thanks for taking the questions. Maybe to start, just so we have a framework of guidance here, what were you assuming for currency in the prior guidance range? What's the currency headwind now assumed in this, just so we can get a better sense of what's FX and what's underlying performance?

Yeah. Hey, good afternoon, Rob. Good to talk to you again. So the original guidance when we provided the range or the point estimate of the billion dollars in February, you know, was at the prevailing rates, you know, at the end of the year. What we're seeing right now with the euro basically, you know, close to parity, we're seeing over $30 million in of FX headwind. As you recall, our dental business is almost half outside of the U.S., and so we're seeing over $30 million of FX headwind in the guidance revision.

Got it. So there was a shortfall in second quarter. Looks like there's more shortfall, I assume, in third and fourth quarter. How should we think about... where the biggest pressure points are, what's assumed in the guidance here relative to market recovery, and I have a few follow-ups after that. Thanks.

Yeah, so let me provide a little bit of color how we're thinking about the balance of the year, and I'll break it up between dental and spine. On the dental business, we guided mid-single digits to mid-high single digits. We expect to be at the lower end of the range. The way I think about it, is uh if q3 sequentially is our is our lower quarter for dental and so what we expect to see um you know is is a kind of a modest decline in q3 due to seasonality and then and then q4 is typically our our strongest quarter and seasonality for dental will largely be roughly the same as it was say in 2019. you know on the on the spine side of things you know we we expect um the balance of the year to be in the low single-digit decline. Again, Q4 is the stronger of the two remaining quarters because of seasonality, but we still expect Q3 to be impacted by seasonality.

Got it. Last for me, the good news is you had good expense control.

Robbie, sorry to interrupt. I think I said low single digit. I meant low double digit decline. My fault.

Got it. Okay. That helps. Good news is expense control was pretty good in the quarter. You know, and you're holding your margin targets here. Maybe speak to where you're seeing the cost savings. Is it coming from variable comp? Are you cutting back on projects? Are you, you know, really... holding spend tight, uh, do the top line and, and, you know, are you more limiting spend or are you reallocating spend that would have been, um, you know, helped, helped, uh, to drive the top line. Thanks. You know, helped, helped, uh, to drive the top line. Thanks.

Hey, Rodney, Zachary here. Yeah, so when we looked at the company and we said we had a number of obstacles that we wanted to overcome, and one was just the operations, primarily within Spine where we were wasting a lot of money in the operations. We didn't have very good DC distribution center performance, and we fixed that. So by early summer, we were back onto service levels we wanted, and that was basically a savings in a sense that we weren't duplicating spend there. But we've been really, really prudent on what we've been spending on, but we haven't done that to sacrifice any projects. So our pipeline looks really good. I'm looking forward to sharing that pipeline with you guys later on as we get a little more granular on what we have. But I think that we are doing well there. And we've really been certain on what we're going to spend on and where the areas we can save on, but we haven't done it at the expense of any kind of commercial, forward commercial activities and projects. Rich, any other thoughts you have on that one?

Yeah, I mean, Robbie, we took some initiatives in the second quarter to really do a number of things, including you know, rationalizing our global footprint, you know, looking at our real estate and determining how much we need, how much we actually don't. We also took some steps to, you know, to right-size the businesses and flatten the organization structure a little bit. And so that's also in there for part of Q2. You know, and as we mentioned before, We're looking to operationalize the business and look to really take out a lot of waste. And so as we're continuing to turn over rocks, we're finding areas of inefficiency. And so we're putting them through the same lens that we have all along and just really kind of scrutinizing what we're spending our money on to make sure that we're getting the best return out of the investments that we are making.

Great. And just last for me, we've moved about a month, month and a half since the end of second quarter. Have you seen any of these difficult trends improve so far over the summer? Any signs of light that some of the pressure points are loosening up? Thanks a lot.

Sure. Internally speaking, we're continuing to make some progress against some of these operational gains we've made. So I think you'll continue to see that theme. So that's a good thing. Macroeconomically, which I think is the crux of your question, I think the summer's been slow. And I think that that's why we're being very conservative into the back half of the year. But I do believe the summer is slow. We don't see, especially outside of the U.S. The U.S. is largely a pretty good market. But outside the U.S., we are seeing, you know, extended vacations, for lack of a better way to explain it. But not necessarily, you know, when we go to visit the customers, we're not seeing a loss of customer. We're seeing an absentee customer on vacation for good reason. So I see that and a CFX being something that will carry on through the rest of the year. Rich, anything else you think?

No, I think that's fair. I think you mentioned it fine.

Great. Thanks a lot.

Thanks, Rob. Thanks, Robbie.

Thank you. And there are no other questions in the queue. I'd like to turn the call back to management for any closing remarks.

Thank you very much for joining the call. Robbie, thanks for your questions. Appreciate the interest. We're feeling really optimistic about the business. It's, again, turnarounds are bumpy, and we're in the early stages, but we feel like we see a path to great things and ultimately a a rich and robust pipeline, as well as a well-operated company. So thank you very much for your time, and we look forward to talking to you in a quarter.

This concludes today's conference call. Thank you for participating. You may now disconnect.